Projects in this Development Area (DA) are predominantly focused on novel cancer treatment drugs and delivery systems, as well as production technologies for diagnostically and therapeutically useful recombinant peptides and proteins. In this DA, we are also continuing our previous work on the bovine transgenic cloning technologies that have brought us considerable international attention, as we witnessed the birth of transgenic cows with human genes for insulin and follicle-stimulating hormone, in 2013 and 2014, respectively. However, these technologies are still hampered by several technological limitations – particularly by the poor health and rates of survival of the transgenic cloned animals. Tackling the technological challenges will enable business application of CCHT research results in the pharmaceutical industry.